#Consumer-Products

2 stories

Industry May 13, 2026 · View digest

Peptide Wellness Market Could Approach $300 Billion as Consumer Demand Accelerates Ahead of July PCAC (May 12 GlobeNewswire)

A May 12 GlobeNewswire industry report frames the consumer peptide wellness market as approaching $300B globally on accelerating mainstream demand for science-backed peptide products spanning energy, recovery, metabolism, healthy aging, fitness, and overall well-being. The report tracks the post-Category-2 commercial cycle for BPC-157, TB-500, GHK-Cu, sermorelin, and the broader peptide supplement and cosmeceutical landscape — including OMI Wellbeauty's hair-growth peptides, Neurogan's 2% GHK-Cu body care, Auro Wellness's copper tripeptide serum, and the early-stage longevity peptide programs at Hims & Hers and LifeMD. The framing arrives six weeks ahead of the FDA's PCAC July 23-24 meeting that will decide compounding-pharmacy status for seven additional peptides including Emideltide (DSIP), Semax, and Epitalon.

Industry May 10, 2026 · View digest

OMI Wellbeauty Launches Hair Growth Peptides Built Around Intermediate Filament Peptide (IFP), Clinical Study Shows 47% Less Shedding at 90 Days

OMI Wellbeauty (founder Naomi Whittel) launched a Hair Growth Peptides supplement line in May 2026, anchored by the Intermediate Filament Peptide (IFP) — a bioactive peptide formulated to support keratin networks in hair follicles and collagen IV production at the root. The double-blind, placebo-controlled 90-day clinical study reported 47% reduction in hair shedding with no significant side effects. The launch sits alongside Neurogan's 2% GHK-Cu body care and Auro Wellness's copper-tripeptide serum as part of the cosmetic and consumer-supplement peptide wave that has been accelerating into the July 2026 PCAC meeting. Unlike compounded peptides, OMI's product is a dietary supplement — not an FDA-approved drug — but the clinical-evidence framing distinguishes it from the broader unregulated peptide-supplement market.